OncoPharm
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Latest episodes
Jul 17, 2025 • 11min
Testicular Cancer in a Nutshell
A brief overview of testicular cancer
Jul 10, 2025 • 11min
Supportive Care Updates
A few supportive care updates:
1. Skin prophylaxis to prevent severe dermatologic toxicity with Nivo/Ipi.
Note* published in JCO Oncology Practice (NOT JAMA Oncol as stated in the episode
Link: https://doi.org/10.1200/OP-25-00100
2. Stampede-Metformin and how metformin has some beneficial effects in prostate cancer patients who don't have diabetes
Link: https://doi.org/10.1016/S1470-2045(25)00231-1
Jul 3, 2025 • 10min
Linvoseltamab & sunvozertinib
Two new drug approvals to talk about (after I misplaced my notes!)
Jun 25, 2025 • 10min
Antiandrogen Withdrawal
Antiandrogen withdrawal is an historically well described phenomenon where prostate cancer patients experience PSA responses AFTER stopping their anti-androgen. But does this happen with today's 2nd generation antiandrogens?
Jun 19, 2025 • 28min
June 2025 Updates
A plethora of recent updates:
-Pembrolizumab (perioperative) in head & neck cancer (Keynote-689)
-Prostate cancer updates on cabozantinib/atezolizumab (yes, really) and talazoparib
-Pirtobrutinib improves PFS in CLL
-Zanubrutinib has a new dosage form on the way
-Another mitomycin product approved with "reverse thermal properties"
-A new regimen for FL of tafasitamab/rituximab/lenalidomide
-A comparison of the new ROS1-inhibitor, taltrectenib, compared to other 1st-line treatment options
Jun 5, 2025 • 14min
ASCO 2025
A recap of notable updates from ASCO 2025
1. Destiny-Breast09
2. BREAKWATER
3. ATOMIC
4. Delphi-304
5. CM 816 OS update
6. C-POST
7. Matterhorn
May 29, 2025 • 11min
CLEOPATRA
Our Landmarks of OncoPharm series returns to discuss the CLEOPATRA study, which established docetaxel, trastuzumab, pertuzumab (THP) as a standard first-line regimen for metastatic HER2-amplified breast cancer.
May 22, 2025 • 15min
Talking about cancer misinformation
If you've been struggling with how to talk to patients about ivermectin for cancer, then this podcast is for you.
1. Cancer misinformation on social media (Loeb, et al): https://doi.org/10.3322/caac.21857
2. Clinician communication with patients about cancer misinformation (Bylund, et al): https://doi.org/10.1200/OP.22.00526
May 22, 2025 • 12min
Four New Drugs
Discussing recent FDA approvals of penpulimab, avutometenib, defactinib, and telisotuzumab vedotin.
May 8, 2025 • 16min
Mg to Prevent Cisplatin Kidney Injury
A splashy large study and two small studies suggest IV Mg in pre-hydration fluids can decrease the risk of cisplatin kidney injury.
Gupta et al. JAMA Oncol (2025): doi:10.1001/jamaoncol.2025.0756
PRAGMATIC. ESMO Open (2022): https://doi.org/10.1016/j.esmoop.2021.100351
Yamamoto et al. Anticancer Res (2015): https://pubmed.ncbi.nlm.nih.gov/25862878/
